{"entity":{"id":"nct07601178","kind":"trial","name":"QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride","aka":[],"tldr":"A phase 2 trial of anlotinib and nab-paclitaxel in triple-negative breast cancer, run by Jiangsu Cancer Institute & Hospital, now recruiting.","summary":"QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer is a phase 2, interventional study registered as NCT07601178 by Jiangsu Cancer Institute & Hospital, with a registry enrolment figure of 34 participants, started 2026-04-17 and due to reach its primary completion in 2027-09-15. Interventions recorded: TREATMENT GROUP（QL1706 + anlotinib+ nab-paclitaxel ）. Conditions listed: TNBC, Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: \"Confirmed by histopathological examination as advanced triple-negative invasive breast cancer, meeting the following criteria: pathological type triple-negative, specifically: ER negative (IHC \\<1%), PR negative (IHC \\<1%), HER2 negative (IHC -/+ or IHC ++ but FISH/CISH negative)\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07601178","url":"https://clinicaltrials.gov/study/NCT07601178"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["anlotinib","nab-paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07601178","phase":"2","setting":"QUEEN-APPLE: A Single-Arm, Multicenter, Prospective Phase II Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Anlotinib Hydrochloride and Nab-Paclitaxel as First-Line Treatment for Advanced Triple-Negative Breast Cancer","sponsor":"Jiangsu Cancer Institute & Hospital","enrolled":34,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07601178/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"anlotinib","kind":"drug","name":"Anlotinib","route":"/drugs/anlotinib/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}